EVE Health Group (ASX: EVE) has boosted the total funds from a recent capital raising to $1.3 million following a $400,000 commitment from a cornerstone investor.
The undisclosed investor has experience in pharmaceutical development, regulatory pathways, and global commercialisation, with their investment reflecting growing support for EVE’s strategy of reformulating established drugs using its proprietary delivery and solubilisation technologies.
Prior to the investment, EVE had raised $904,000 via the issue of 45.2 million shares priced at $0.02 each.
Participants also received two free attaching unlisted options for every share subscribed, exercisable at $0.04 and expiring two years from issue.
Reformulating Compounds
EVE is focused on developing reformulated versions of established pharmaceutical compounds using novel delivery systems to improve bioavailability, onset of action and patient convenience.
The strategy focuses on medicines approaching patent expiry where improved delivery formats may provide differentiated products that can be commercialised through licensing or supply partnerships with pharmaceutical companies that have established regulatory capabilities, manufacturing infrastructure, and distribution networks.
The approach offers significant advantages over traditional drug discovery pathways using known safety profiles to reduce clinical development risk, targeting large markets with predictable demand and employing shorter development timelines compared to novel drug development.
EVE is advancing a growing pipeline of drug candidates targeting global markets including sexual health therapies and cardiovascular treatments which are estimated to exceed US$30 billion annually.
Scientific Board Appointment
EVE also recently announced the appointment of Dr Sama Balasubramanian to the company’s scientific advisory board.
Dr Balasubramanian is a specialist sexual health physician and general practitioner with extensive experience across clinical practice, medical education and health governance.
He holds fellowships with the Royal Australian College of General Practitioners, the Australasian Chapter of Sexual Health Medicine, and the European Committee of Sexual Medicine, as well as an advanced masters in psychosexual therapy with the University of Sydney.
He has held a number of senior industry leadership positions including chair of the training committee in sexual health medicine with the Royal Australasian College of Physicians and president of General Practice Registrars Australia in areas such as curriculum development, clinical governance, trainee supervision, and national policy advisory.
Dr Balasubramanian joins EVE at a time when the company is managing the commercial launch of Libbo oral dissolving film treatment for erectile dysfunction and building an integrated digital prescribing and fulfilment platform to support scalable national access.
